AVEO Pharmaceuticals (STU:VPA1) Net Change in Cash : €8.33 Mil (TTM As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

AVEO Pharmaceuticals's Net Change in Cash for the three months ended in Sep. 2022 was €7.30 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 was €8.33 Mil.

AVEO Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for AVEO Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Net Change in Cash Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Change in Cash

Get a 7-Day Free Trial

-0.12

8.33

4.82

26.29

7.77

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Net Change in Cash	Get a 7-Day Free Trial															-5.01	1.51	3.00	-3.48	7.30

AVEO Pharmaceuticals Net Change in Cash Calculation

AVEO Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-50.672	+	-14.926	+	73.37	+	0
	=	7.77

AVEO Pharmaceuticals's Net Change in Cash for the quarter that ended in Sep. 2022

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0.196 + 7.07 + 0.036 + 0

= 7.30

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AVEO Pharmaceuticals Net Change in Cash Related Terms
Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (STU:VPA1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Net Change in Cash

Comparable Companies

SLGL IOBT OBSV CLNN RVLP ABOS SCPH PDSB CFRX CTXR OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines